J Goodwin to Gonadotropin-Releasing Hormone
This is a "connection" page, showing publications J Goodwin has written about Gonadotropin-Releasing Hormone.
Connection Strength
0.841
-
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006 Feb 27; 166(4):465-71.
Score: 0.244
-
Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005 Apr 15; 103(8):1615-24.
Score: 0.230
-
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005 Jan 13; 352(2):154-64.
Score: 0.226
-
Kuo YF, Goodwin JS, Shahinian VB. Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer. BMC Health Serv Res. 2008 Jul 14; 8:146.
Score: 0.072
-
Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer. J Clin Oncol. 2007 Dec 01; 25(34):5359-65.
Score: 0.069